Drugs / MNI-388
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00886951 | Mar 2009 | Alzheimer disease | Institute for Neurodegenerative Disorders | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MNI-388 | “The primary imaging outcome measure will be the brain regional distribution volumes expressed as a brain tissue to plasma ratio of the radioligand, 123-I MNI-388 and MNI-390.” NCT00886951 ↗ |
| Known as | 123-I MNI-388 | “Subjects will be given a bolus injection of 123-I MNI-388 and MNI 390 in an antecubital vein.” NCT00886951 ↗ |
| Route | Intravenous | “Subjects will be dosed by intravenous injection” NCT00886951 ↗ |